Arend Mosterd is a cardiologist at Meander Medical Center, Amersfoort, The Netherlands. Currently he chairs the scientific advisory board of the Dutch Heart Foundation.
He is co-principal investigator of the Australian Dutch LoDoCo2 study (A double blind, placebo controlled, randomized trial of low dose colchicine in the secondary prevention of cardiovascular in 5.522 patients with coronary artery disease) the main results of which were published in the New England Journal of Medicine in 2020. This trial has led to a paradigm shift in the anti-inflammatory treatment of patients with coronary artery disease and serves as a prime examples of drug repurposing.
He studied Medicine at Utrecht University Medical School (M.D. degree 1990) and obtained his PhD degree at Erasmus University Rotterdam with a thesis on the epidemiology of heart failure (1997). He was trained in clinical epidemiology at Erasmus Medical Center Rotterdam and the Framingham Heart Study (USA). His cardiology training took place at the Thorax Center in Rotterdam.
He has served on several Netherlands Health Council committees, drafted practice guidelines and was instrumental in the development of the research agenda of the Netherlands Heart Foundation. He is a fellow of the European Society of Cardiology (FESC) and a member of the Netherlands Society of Cardiology. From 2012 to 2014 chaired the working group on heart failure of the Netherland Society of Cardiology. In 2012 he joined the Board of the Dutch Network for Cardiovascular Research (WCN; www.wcn.life), an association of 59 cardiovascular research centers, and served as Chair of the WCN from 2013 through 2019.
